Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...
A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint ...
Delivering drugs to gut tumors can be tricky. Researchers at Washington University in St. Louis have engineered an oral probiotic yeast to do the work for them, with the fungal cells able to release ...
- Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA® or OPDIVO® can result in improved patient outcomes - MDSCs – Myeloid Derived Suppressor Cells in the tumor ...
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has entered into a collaboration and supply agreement with BeiGene, Ltd. (to be changed to BeOne Medicines, ...
Another checkpoint inhibitor has entered the fray, as Checkpoint Therapeutics has passed the FDA’s checkpoint with its PD-L1 inhibitor cosibelimab. The FDA has approved cosibelimab under the brand ...
The Oncologic Drugs Advisory Committee (ODAC) decided 10-2 with one abstention that PD-1 inhibitors do not have a favorable risk/benefit profile in gastric/gastroesophageal junction (GEJ) cancers with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback